Yongping Shao, PhD

Kimmel Cancer Center at Jefferson

Yongping Shao, Ph.D.

  • PhD, Molecular Biology, State University of New York at Albany
  • MS, Botany, Fudan University, Shanghai, China
  • BS, Biology, Fudan University, Shanghai, China
Research Focus:

Dr. Shao’s study is entitled, “Mechanism of acquired resistance to B-RAF inhibitor in melanoma.” Various genetic alterations have been identified in melanoma with B-RAF (~50%) and RAS (~15%) mutations being the most common ones. One B-RAF mutant, V600E, which increases B-RAF kinase activity and hyperactivates the MEK-ERK 1/2 pathway has been found in about 90% of all mutant B-RAF melanomas and therefore serves as a good candidate for targeted therapy.

A recently developed inhibitor, PLX4032, blocks B-RAF activation of the MEK-ERK 1/2 pathway selectively in mutant B-RAF cells. PLX4032 achieved a striking 78% responsive rate with >30% tumor regression in a phase I clinic trial on mutant B-RAF (V600E) patients indicating a cytotoxic effect of this inhibitor.

The study is hoped to provide valuable knowledge on the molecular basis of drug resistance in melanoma.

Yongping Shao, Ph.D.

2011 Outrun the Sun Melanoma Research and Education Forum:

Yongping Shao – Power Point Slides

Yongping Shao – Audio

« Back to Scholar Overview

Copyright 2021 Outrun the Sun, Inc.
Name and Logo are registered trademarks.
Site Design by Mitre Agency